Learn About Chronic Myelomonocytic Leukemia (CMML)
View Main Condition: Leukemia
PDGFRB-associated chronic eosinophilic leukemia is a type of cancer of blood-forming cells. It is characterized by an elevated number of white blood cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRB-associated chronic eosinophilic leukemia. Some people with this condition have an increased number of other types of white blood cells, such as neutrophils or mast cells, in addition to eosinophils. People with this condition can have an enlarged spleen (splenomegaly) or enlarged liver (hepatomegaly). Some affected individuals develop skin rashes, likely as a result of an abnormal immune response due to the increased number of eosinophils.
PDGFRB-associated chronic eosinophilic leukemia is caused by genetic rearrangements that join part of the PDGFRB gene with part of another gene. At least 20 genes have been found that fuse with the PDGFRB gene to cause PDGFRB-associated chronic eosinophilic leukemia. The most common genetic abnormality in this condition results from a rearrangement (translocation) of genetic material that brings part of the PDGFRB gene on chromosome 5 together with part of the ETV6 gene on chromosome 12, creating the ETV6-PDGFRB fusion gene.
The exact prevalence of PDGFRB-associated chronic eosinophilic leukemia is unknown. For unknown reasons, males are up to nine times more likely than females to develop PDGFRB-associated chronic eosinophilic leukemia.
PDGFRB-associated chronic eosinophilic leukemia is not inherited and occurs in people with no history of the condition in their families. Chromosomal rearrangements that lead to a PDGFRB fusion gene are somatic variants, which are variants acquired during a person's lifetime and present only in certain cells. The somatic variant occurs initially in a single cell, which continues to grow and divide, producing a group of cells with the same variant (a clonal population).
Vidant Medical Group LLC
John Inzerillo is a Hematologist Oncology specialist and a Hematologist in Washington, North Carolina. Dr. Inzerillo and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Childhood Iron Deficiency Anemia, and Acute Mountain Sickness. Dr. Inzerillo is currently accepting new patients.
East Carolina University
Lacy Hobgood is a Pediatrics specialist and an Internal Medicine provider in Greenville, North Carolina. Dr. Hobgood and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency, Acute Interstitial Pneumonia, Spasticity, Endoscopy, and Gastrostomy. Dr. Hobgood is currently accepting new patients.
Carolinaeast Physicians
William Taylor is a Hematologist Oncology specialist and an Oncologist in New Bern, North Carolina. Dr. Taylor and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Inflammatory Breast Cancer. Dr. Taylor is currently accepting new patients.
Summary: This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Summary: This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant (bone marrow transplant). The goal of this research study is to (1) test the sa...
Published Date: December 09, 2022
Published By: National Institutes of Health